XML 31 R15.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Stockholders' Equity | 12 Months Ended
--- | ---
Dec. 31, 2017
Stockholders' Equity [Abstract] |
Stockholders' Equity | NOTE 9. STOCKHOLDERS’ EQUITY Preferred Stock Our Certificate of Incorporation, as amended and restated in October 2010 in connection with the closing of our initial public offering, authorizes us to issue 1,000,000,000 shares of $0.001 par value common stock and 50,000,000 shares of $0.001 par value preferred stock. As of December 31, 2017 and 2016, there were no shares of preferred stock issued or outstanding. Common Stock Common stockholders are entitled to dividends when and if declared by our board of directors. There have been no dividends declared to date. The holder of each share of common stock is entitled to one vote. For the year ended December 31,2016, we issued 6.5 million shares of our common stock at an average price of $9.19 through our “at-the-market” offering, resulting in net proceeds of $58.2 million. In February 2017, we filed a prospectus supplement pursuant to which we could offer and sell, from time to time, additional shares of our common stock having an aggregate offering price of up to $60.0 million. During 2017 we issued 3.2 million shares of our common stock at an average price of $3.86 per share through our “at-the-market” offering, resulting in net proceeds of $11.9 million. We terminated our “at-the-market” offering program in June 2017. We paid a commission equal to 3% of the gross proceeds from the sale of shares of our common stock under the sales agreement. In August 2017, we filed a shelf registration statement on Form S-3 with the SEC pursuant to which we may, from time to time, sell up to an aggregate of $150.0 million of our common stock, preferred stock, depository shares, warrants, units or debt securities. On August 18, 2017, the registration statement was declared effective by the SEC, which allows us to access the capital markets for the three-year period following this effective date. Underwritten Public Equity Offering In June 2017, we issued and sold a total of 17.7 million shares of our common stock at a price to the public of $3.10 per share in an underwritten public offering. We paid a commission equal to 4% of the gross proceeds from the sale of shares of our common stock under the underwriting agreement. The total proceeds to us from the offering, after deducting the underwriting commission and offering expenses, were approximately $52.5 million. In February 2018, we issued and sold a total of 14,375,000 shares of our common stock at a price to the public of $2.40 per share in an underwritten public offering. We paid a commission equal to 4% of the gross proceeds from the sale of shares of our common stock under the underwriting agreement. The total net proceeds to us from the offering, after deducting the underwriting commission and estimated offering expenses, were approximately $32.8 million. We may need to raise additional capital in the future through the sale of equity or convertible debt securities, including future “at-the-market” offerings. Subject to certain exceptions set forth in our existing Facility Agreement, holders of our Notes may elect to receive 25% of the net proceeds from financing activities that include an equity component as prepayment of the Notes to be applied first, to accrued and unpaid interest and second, to principal. To the extent we raise additional capital in the future through the sale of common stock, including without limitation, sales of common stock pursuant to an “at-the-market” offering program, we may be obligated, at the election of the holders, to pay 25% of the net proceeds from any such financing activities as partial payment of the Notes. Warrants In connection with the execution of the Facility Agreement, we issued immediately exercisable warrants to purchase 5.5 million shares of common stock at an exercise price per share initially equal to $2.63, all of which were net exercised during 2016 resulting in the issuance of approximately 4.2 million shares. The cashless net exercise of the warrants did not result in any additional funds being collected by us. As of December 31, 2017 and 2016, no warrants remained outstanding. Equity Plans As of December 31, 201 7, we had three active equity plans: 1) the 2010 Equity Incentive Plan or “2010 Plan,” 2) the 2010 Outside Director Equity Incentive Plan or “2010 Director Plan,” and 3) the 2010 Employee Stock Purchase Plan or “ESPP”, all of which we adopted upon the effectiveness of our initial public offering in October 2010. Prior to the adoption of these plans, we granted options pursuant to the 2004 Equity Incentive Plan and 2005 Stock Plan. Upon termination of the predecessor plans, the shares available for grant at the time of termination, and shares subsequently returned to the plans upon forfeiture or option termination, were transferred to the successor plan in effect at the time of share return. We issue new shares of common stock upon the exercise of stock options. 2010 Equity Incentive Plan and Outside Director Equity Incentive Plan Stock options granted under the 2010 Plan may be either Incentive Stock Option (“I SO”) or Non-Qualified Stock Option (“NSO”). ISOs may be granted only to employees. NSOs may be granted to employees, consultants and directors. Stock options under the 2010 Plan may be granted with a term of up to ten years and at prices no less than the fair market value of our common stock on the date of grant. To date, stock options granted to existing employees generally vest over four years on a monthly basis and stock options granted to new employees vest at a rate of 25% upon the first anniversary of the vesting commencement date and 1/48th per month thereafter. In January 201 8, an additional 7.0 million shares were reserved under the 2010 Plan. Stock options granted under the 2010 Director Plan provide for the grant of NSOs. Stock options under the 2010 Plan may be granted with a term of up to ten years and at prices no less than the fair market value of our common stock on the date of grant. To date, stock options granted to existing directors generally vest over one year on a monthly basis and stock options granted to new directors generally vest over three years at a rate of one-third upon the first anniversary of the vesting commencement date and 1/36th per month thereafter. As of December 31, 201 7 we had an aggregate of 6.8 million shares of common stock reserved for future issuance under the 2010 Plan and 2010 Director Plan. 2010 Employee Stock Purchase Plan We adopted the ESPP in October 2010. Our ESPP permits eligible employees to purchase common stock at a discount through payroll deductions during defined offering periods. Each offering period will generally consist of four purchase periods, each purchase period being approximately six months. The price at which the stock is purchased is equal to the lower of 85% of the fair market value of the common stock at the beginning of an offering period or at the end of a purchase period. Each offering period will generally end and the shares will be purchased twice yearly on March 1 and September 1. If the stock price at the end of the purchase period is lower than the stock price at the beginning of the offering period, that offering period will then be terminated and new offering period comes to place. As of December 31, 201 7, 1.3 million s hares of our common stock remain available for issuance under the Plan. The ESPP provides for an annual increase to the shares available for issuance at the beginning of each calendar year equal to 2% of the common shares then outstanding. During January 201 8, an additional 2.3 million shares were reserved under the ESPP. The following table summarizes stock option activity for all stock option plans for the year ended December 31, 201 7 (in thousands, except per share amounts): ﻿
﻿ |  |  |  |  |  |  |  |  |
﻿ |  |  |  |  |  |  |  |  |
﻿ |  |  | Stock Options Outstanding
﻿ | Shares available |  | Number |  |  |  |  | Weighted average
﻿ | for grant |  | of shares |  | Exercise price |  | exercise price
﻿Balances, December 31, 2016 | 6,471 |  | 22,501 |  | $ | 1.16 – 16.00 |  | $ | 6.30
﻿Additional shares reserved | 4,634 |  |  |  |  |  |  |  |
﻿Options granted | (6,239) |  | 6,239 |  | $ | 2.66 – 5.37 |  | $ | 4.84
﻿Options exercised | — |  | (1,407) |  | $ | 1.16 – 5.27 |  | $ | 2.55
﻿Options canceled | 1,929 |  | (1,929) |  | $ | 1.16 – 16.00 |  | $ | 7.00
﻿Balances, December 31, 2017 | 6,795 |  | 25,404 |  | $ | 1.16 – 16.00 |  | $ | 6.10
﻿ ﻿ The following table summarizes information with respect to stock options outstanding and exercisable under the plans at December 31, 2017: ﻿
﻿ |  |  |  |  |  |  |  |  |  |  |
﻿ |  |  |  |  |  |  |  |  |  |  |
﻿ | Options Outstanding |  | Options Exercisable
﻿ |  |  | Weighted average |  |  |  |  |  |  |  |
﻿ | Number |  | remaining contractual |  | Weighted average |  | Number |  | Weighted average
﻿ | outstanding |  | life (Years) |  | exercise price |  | vested |  | exercise price
﻿ | 25,404,152 |  | 6.51 |  | $ | 6.10 |  | 16,802,740 |  | $ | 6.05
﻿ The aggregate intrinsic value of the outstanding and exercisable options presented in the table above totaled $1.7 million and $1.6 million, respectively. The aggregate intrinsic value represents the total pretax intrinsic value (i.e., the difference between $2.64, our closing stock price on the last trading day of our fourth quarter of 2017 and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their options on December 31, 201 7. The aggregate intrinsic value changes at each reporting date based on the fair market value of our common stock. The weighted average remaining contractual life for exercisable options is 5.43 years. The vested and expected to vest option as of December 31, 2017 totaled 22,324,228, with aggregate intrinsic value of $1.6 million, weighted average exercise price per share of $6.04 and weighted average remaining contractual life of 6.23 years. The total intrinsic v alue of stock options exercised during the years ended December 31, 2017, 2016 and 2015 was $1.7 million, $4.7 million and $3.5 million, respectively. The total fair valu e of stock options vested during the years ended December 31, 2017, 2016 and 2015 was $6.4 million, $20.7 million and $7.3 million, respectively. Stock-based Compensation Total stock-based compensation expense consists of the following (in thousands): ﻿
﻿ |  |  |  |  |  |  |  |
﻿ |  |  |  |  |  |  |  |
﻿ | Years Ended December 31,
﻿ | 2017 |  | 2016 |  | 2015
﻿Cost of revenue | $ | 2,311 |  | $ | 2,133 |  | $ | 1,313
﻿Research and development |  | 8,506 |  |  | 8,257 |  |  | 5,196
﻿Sales, general and administrative |  | 9,535 |  |  | 9,172 |  |  | 7,331
﻿Total stock-based compensation expense | $ | 20,352 |  | $ | 19,562 |  | $ | 13,840
﻿ As of December 31, 201 7 and December 31, 201 6, $441,000 and $389,000 of stock-based compensation cost was capitalized in inventory on our consolidated balance sheets, respectively. The tax benefit of stock-based compensation expense was immaterial for the years ended December 31, 2017, 2016 and 2015. Stock Options We estimated the fair value of employee stock option using the Black-Scholes option pricing model. The fair value of employee stock options is being amortized on a straight-line basis over the requisite service period of the awards. For the years ended December 31, 2017, 2016 and 2015, the weighted average fair value at grant date per stock option was $3.08, $5.47 and $4.75, respectively. We recorded stock-based compensation expense for stock options of $17.2 million, $15.7 million and $10.2 million for the years ended December 31, 2017, 2016 and 2015, respectively. For the years ended December 31, 2017, 2016 and 2015, the fair value of employee stock options was estimated using the following weighted average assumptions: ﻿
﻿ |  |  |  |  |  |  |  |  |
﻿ |  |  |  |  |  |  |  |  |
﻿ |  | Years Ended December 31,
﻿ |  | 2017 |  | 2016 |  | 2015
﻿Expected term (years) |  |  | 6.1 years |  |  | 6.1 years |  |  | 6.1 years
﻿Expected volatility |  |  | 70.0% |  |  | 70.0% |  |  | 70.0%
﻿Risk-free interest rate |  |  | 2.1% |  |  | 1.5% |  |  | 1.7%
﻿Dividend yield |  |  | — |  |  | — |  |  | —
﻿ |  |  |  |  |  |  |  |  |
﻿ As of December 31, 201 7, $22.5 million of total unrecognized compensation expense related to stock options was expected to be recognized over a weighted-average period of 2.5 years. Future option grants will increase the amount of compensation expense to be recorded in those future periods. Cash received from option exercises for the years ended December 31, 2017, 2016 and 2015 was $3.6 million, $2.5 million and $3.0 million, respectively. ESPP We estimated the fair value of ESPP using the Black-Scholes option pricing model. For the years ended December 31, 2017, 2016 and 2015, weighted average fair value at grant date for ESPP was $2.28, $4.21 and $2.20, respectively. We recorded stock-based compensation expense for ESPP of $3.1 million, $3.7 million and $3.6 million for the years ended December 31, 2017, 2016 and 2015, respectively. For the years ended December 31, 2017, 2016 and 2015, the fair value of ESPP was estimated using the following assumptions:
﻿ |  |  |  |  |  |  |  |  |
﻿ |  |  |  |  |  |  |  |  |
﻿ |  | Years Ended December 31,
﻿ |  | 2017 |  | 2016 |  | 2015
﻿Expected term (years) |  |  | 0.5 - 2.0 |  |  | 0.5 - 2.0 |  |  | 0.5 - 2.0
﻿Expected volatility |  |  | 70.0% |  |  | 70.0% |  |  | 70.0%
﻿Risk-free interest rate |  |  | 0.8%-1.4% |  |  | 0.5%-0.9% |  |  | 0.1%-0.7%
﻿Dividend yield |  |  | — |  |  | — |  |  | —
﻿ For the years ended December 31, 2017 and 2016 and 2015, 1.3 million shares, 1.3 million shares and 1.1 million shares of common stock were purchased under the ESPP, respectively. Cash received through the ESPP for the years ended December 31, 2017, 2016 and 2015 was $5.3 million, $5.2 million and $4.4 million, respectively.

X
- References No definition available. + Details
Name: | us-gaap_StockholdersEquityNoteAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -URI http://asc.fasb.org/topic&trid=2208762 + Details
Name: | us-gaap_StockholdersEquityNoteDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration